Latest total current liabilities for PNT: $39M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
POINT Biopharma Global (PNT) currently reports a total current liabilities of $39M as of September 2023. That compares with $17M in the prior-year period — up 132.8% year over year. Use the charts on this page to explore POINT Biopharma Global's total current liabilities history and peer comparisons.
POINT Biopharma Global's total current liabilities increased from $17M to $39M — a 132.8% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
POINT Biopharma Global reported $39M in total current liabilities as of September 2023. That compares with $17M in the prior-year period — up 132.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $39M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for POINT Biopharma Global, and consider following PNT for alerts when major investors trade the stock.
POINT Biopharma Global is classified in the Healthcare sector. On total current liabilities, it currently shows $39M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PNT with unrelated industries.